Current evidence is not strong enough for AI to change an individual treatment or surgery decision safely, and models used to estimate response are not interchangeable across subtypes and must be read in their original treatment context.
Abstract
Simple Summary Breast cancer comprises biologically distinct subtypes rather than a single disease, and each is treated with a different pre-surgery strategy. Clinicians want to know early whether a patient is likely to respond, because that could guide safer treatment adjustment. Artificial intelligence has therefore been used to estimate response from routinely collected imaging, pathology slides, and laboratory data, using models that range from statistical scores to deep-learning systems and multimodal designs. This review finds such estimates are not interchangeable across subtypes and must be read in their original treatment context. Most models were tested only where they were built, few in independent patients, and fewer still for reliable probabilities or improved decisions. Current evidence is therefore not strong enough for AI to change an individual treatment or surgery decision safely. We map how mature the evidence is, how it differs across subtypes, and what is still required.
The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons, and out-performed existing recurrence-score-based tests.
D. Biswas, Jeroen Berrevoets, A. McClean et al.· 3 citations
Artificial Intelligence (AI) has become an important tool in medical diagnostics by enabling models to learn complex relationships between historical patient data and current clinical indicators, supporting earlier and more accurate disease detection. Ovarian cancer remains particularly challenging to diagnose because...
A. Shetty, Prachetas Sujit Chandratreya, Bhargav Sanjeev Gejji et al.· International Conference on...· 0 citations
Extensive validation will be needed to convert PATH-ORACLE from a prognostic biomarker to a predictive biomarker that could be used to prioritize stage IB patients for adjuvant targeted therapy, chemotherapy, or immune checkpoint inhibitor therapy with or without liquid biopsy-based monitoring.
O. Kilim, O. Pipek, Z. Sztupinszki et al.· Immuno-Oncology Technology· 0 citations
A novel multimodal deep learning approach that combines pre-treatment dynamic contrast-enhanced MRI and clinical data for predicting pCR before chemotherapy, and is the first to integrate attention-based multiple instance learning technique for slice aggregation and a self-supervised contrastive objective to align imag...
Manu Goyal, Tanmay Shukla, Saeed Hassanpour· Journal of imaging informati...· 0 citations
A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.
Jungkyu Park, D. Biswas, J. Cappadona et al.· 0 citations
Current AI applications in lung cancer related to radiologic imaging, digital pathology, genomics, immunohistochemistry, and Cell Painting morphology are examined and their potential to be incorporated into a proposed multimodal model is examined.
T. Chakrabarti, A. Mansour, Xi-Wei Wu et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.